Corrigendum to "Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor" [Bioorg. Med. Chem. Lett. 18 (2008) 571-575] (DOI:10.1016/j.bmcl.2007.11.077);Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 571-575

  Lee, Ga Eun ^a   Joshi, Bhalchandra V ^b   Chen, Wangzhong ^b   Jeong, Lak Shin ^c   Moon, Hyung Ryong ^d   Jacobson, Kenneth A ^b   Kim, Yong Chul ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c Ewha Womans University   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Ethidium bromide uptake; IL 1 release; P2X7 receptor; Tyrosine based antagonists

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; ETHIDIUM BROMIDE; INTERLEUKIN 1BETA; PIPERAZINE; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TYROSINE DERIVATIVE;

ARTICLE; CELL STRAIN HEK293; CYTOKINE RELEASE; DRUG DETERMINATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

EID: 38149132392     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.108     Document Type: Erratum

References (29)

1. Fredholm B.B., Abbracchio M.P., Burnstock G., Dubyak G.R., Harden T.K., Jacobson K.A., Schwabe U., and Williams M. Trends Pharmacol. Sci. 18 (1997) 79
2. Ralevic V., and Burnstock G. Pharmacol. Rev. 50 (1998) 413
3. Surprenant A., Rassendren F., Kawashima E., North R.A., and Buell G. Science 272 (1996) 735
4. Di Virgilio F. Immunol. Today 16 (1995) 524
5. Sikora A., Liu J., Brosnan C., Buell G., Chessel I., and Bloom B.R. J. Immunol. 163 (1999) 558
6. Sluyter R., Barden J.A., and Wiley J.S. Cell. Tissue Res. 304 (2001) 231
7. Schulman E.S., Glaum M.C., Post T., Wang Y., Raible D.G., Mohanty J., Butterfield J.H., and Pelleg A. Am. J. Respir. Cell Mol. Biol. 20 (1999) 530
8. Di Virgilio F., Sanz J.M., Chiozzi P., and Falzoni S. Prog. Brain Res. 120 (1999) 355
9. Jacobson K.A., Jarvis M.F., and Williams M. J. Med. Chem. 45 (2002) 4057
10. Smart M.L., Gu B., Panchal R.G., Wiley J., Cromer B., Williams D.A., and Petrou S. J. Biol. Chem. 278 (2003) 8853
11. Denlinger L.C., Fisette P.L., Sommer J.A., Watters J.J., Prabhu U., Dubyak G.R., Proctor R.A., and Bertics P.J. J. Immunol. 167 (2001) 1871
12. Kim M., Jiang L.H., Wilson H.L., North R.A., and Surprenant A. EMBO J. 20 (2001) 6347
13. Virginio C., MacKenzie A., North R.A., and Surprenant A. J. Physiol. 519 Pt 2 (1999) 335
14. Michel A.D., Kaur R., Chessell I.P., and Humphrey P.P. Br. J. Pharmacol. 130 (2000) 513
15. North R.A. Physiol. Rev. 82 (2002) 1013
16. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., and Di Virgilio F. J. Immunol. 176 (2006) 3877
17. Loomis W.H., Namiki S., Ostrom R.S., Insel P.A., and Junger W.G. J. Biol. Chem. 278 (2003) 4590
18. Mehta V.B., Hart J., and Wewers M.D. J. Biol. Chem. 276 (2001) 3820
19. Suzuki T., Hide I., Ido K., Kohsaka S., Inoue K., and Nakata Y. J. Neurosci. 24 (2004) 1
20. Baraldi P.G., Di Virgilio F., and Romagnoli R. Curr. Top. Med. Chem. 4 (2004) 1707
21. Clyne C.D., Nguyen A., and Rainey W.E. Endocr. Res. 21 (1995) 259
22. Chen W., Ravi R.G., Kertesy S.B., Dubyak G.R., and Jacobson K.A. Bioconjug. Chem. 13 (2002) 1100
23. Baraldi P.G., Romagnoli R., Tabrizi M.A., Falzoni S., and Di Virgilio F. Bioorg. Med. Chem. Lett. 10 (2000) 681
24. Baraldi P.G., del Carmen Nunez M., Morelli A., Falzoni S., Di Virgilio F., and Romagnoli R. J. Med. Chem. 46 (2003) 1318
25. Alcaraz L., Baxter A., Bent J., Bowers K., Braddock M., Cladingboel D., Donald D., Fagura M., Furber M., Laurent C., Lawson M., Mortimore M., McCormick M., Roberts N., and Robertson M. Bioorg. Med. Chem. Lett. 13 (2003) 4043
26. Merriman G.H., Ma L., Shum P., McGarry D., Volz F., Sabol J.S., Gross A., Zhao Z., Rampe D., Wang L., Wirtz-Brugger F., Harris B.A., and Macdonald D. Bioorg. Med. Chem. Lett. 15 (2005) 435
27. Nelson D.W., Gregg R.J., Kort M.E., Perez-Medrano A., Voight E.A., Wang Y., Grayson G., Namovic M.T., Donnelly-Roberts D.L., Niforatos W., Honore P., Jarvis M.F., Faltynek C.R., and Carroll W.A. J. Med. Chem. 49 (2006) 3659
28. + was determined by measuring fluorescence with a fluorescent plate reader (excitation filter of 530/20 and emission filter of 590/20).
29. Inhibition effects of BzATP-mediated IL-1β release by ELISA measurements. IL-1β release was measured in differentiated THP-1 cells primed for 3 h with 25 ng/ml LPS and 10 ng/ml IFNγ, and then was stimulated with 1 mM BzATP for 30 min. Synthesized tyrosine-based derivatives at 1 μM were treated for 30 min prior to BzATP. Supernatants were collected by centrifugation at 1000 rpm for 5 min and assayed for the presence of mature human IL-1β using an ELISA kit.